ClinicalTrials.govpublic full text
Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II
biliary tract cancer (btc), egfr-positive advanced biliary tract carcinoma, becotatug vedotin, pucotenlimab, egfr-adc, pd-1, second-line, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 909046
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.